NCT02926430View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 8, 2016

Primary Completion Date

March 14, 2018

Study Completion Date

January 29, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.RSV.preF 5*10^10 vp

Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).

BIOLOGICAL

Ad26.RSV.preF 1*10^11 vp

Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).

DRUG

Placebo

Participants will receive placebo as formulation buffer.

Trial Locations (1)

Unknown

Miami

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT02926430 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health | Biotech Hunter | Biotech Hunter